Adenocarcinoma of the pancreas remains a highly lethal disease, with less than 5% survival
at 5 years. Borderline resectable pancreatic cancer (BRPC) and locally advanced …

Learning Objectives After completing this course, the reader will be able to: Discuss the
natural history of locally advanced pancreatic cancer, compared with resectable or …

Purpose: The size of polymeric nanoparticles is considered as an effective factor in cancer
therapy due to enterance into tumor tissue via the EPR effect. The purpose of this work was …

Abstract AURKA/STK15/BTAK, the gene encoding Aurora A kinase that is involved in the
regulation of centrosomes and segregation of chromosomes, is frequently amplified and …

PURPOSE: To evaluate the toxicity of a preoperative regimen of paclitaxel and concurrent
external-beam radiation therapy, pancreaticoduodenectomy, and electron-beam …

Background The most accepted treatment for locally advanced pancreatic cancer is
chemoradiotherapy. However, indications to and results of pancreatic resections after …

Purpose: The optimal strategy for treating locally advanced pancreatic cancer remains
controversial, including the respective roles and timing of chemotherapy and radiation. We …

Unresectable cancer of the pancreas was treated with the combination of weekly paclitaxel
and external beam irradiation in an effort to improve palliation and extend life expectancy …

Objectives: To determine the maximal tolerated dose (MTD) and dose limiting toxicities of
poly (l-glutamic acid)-paclitaxel (PPX) and concurrent radiation (PPX/RT) for patients with …

Objectives: A phase I trial was conducted to determine the maximally tolerated dose of
erlotinib with concurrent gemcitabine, paclitaxel, and radiation for patients with locally …